My watch list  


Vernalis plc
Founded2003 from merger
HeadquartersWinnersh, United Kingdom
Key peopleCEO
Robert Mansfield, 1992-2003
Simon Sturge, 2003-
George Kennedy, 2000-2003
Peter Fellner, 2003-
ProductsFrovatriptan, Apokyn

Vernalis Plc is a British based biotech company founded in 2003 by the merger of Vernalis Group with British Biotech in a deal valued at £90 million.[1] The merger allowed British Biotech to ditch its historic but tarnished name.[2]

The company has marketed two drug products; Frovatriptan,,[3] to treat migraine, and Apokyn, an apomorphine-based drug for advanced Parkinson's disease.[4]

The company has a development pipeline focused on CNS disease and oncology, and collaborates with pharmaceutical companies including Novartis, Servier, ChemGenex and Serono.


  1. ^ Vernalis agrees £91m merger plan with British Biotech. Advances in Life Science. ALS (2003). Retrieved on 2003-07-03.
  2. ^ Fifth Report. Select Committee on Science and Technology. House of Commons (1998). Retrieved on 2007-11-28.
  3. ^ Patient Information Sheet -- Frovatriptan succinate (marketed as Frova). Food and Drug Administration (07/2006). Retrieved on 2007-11-28.
  4. ^ Apokyn. FDA (2004). Retrieved on 2004-07-29.
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Vernalis". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE